Drilldown: Medicines
More actions
Use the filters below to narrow your results.
APL)]] (1) ·
[[:Category:Antidepressants|Antidepressant]] (1) ·
[[:Category:Antimetabolites|Antimetabolite (pyrimidine analog)]] (1) ·
[[:Category:Antineoplastics|Antineoplastic (oral (1) ·
[[:Category:Antineoplastics|Antineoplastic]] (1) ·
[[:Category:Anxiolytics|Anxiolytic]] (1) ·
[[:Category:B-vitamins|B-vitamin]] (1) ·
[[:Category:Retinoids|Retinoid]] (1) ·
[[:Category:Selective Serotonin Reuptake Inhibitors (SSRIs)|SSRI]] (1) ·
[[:Category:Topical_retinoids|Topical retinoid]] (1) ·
[[:Category:Vitamins|Vitamin]] (1)
None (2) ·
TrkB/BDNF'"`UNIQ--ref-00000040-QINU`"' '"`UNIQ--vote-00000041-QINU`"' (1) ·
'"`UNIQ--vote-0000124C-QINU`"' The 400 mg/d dose for migraine prophylaxis is supported by randomized trials (Schoenen 1998) and remains a low-risk evidence-based supplement option. Characteristic bright-yellow urine fluorescence with high-dose oral supplementation. (1)
'"`UNIQ--vote-00000042-QINU`"', '"`UNIQ--vote-00000043-QINU`"', '"`UNIQ--vote-00000044-QINU`"' (1) ·
'"`UNIQ--vote-00000BA0-QINU`"', '"`UNIQ--vote-00000BA1-QINU`"', '"`UNIQ--vote-00000BA2-QINU`"' (1) ·
'"`UNIQ--vote-000011BA-QINU`"', '"`UNIQ--vote-000011BB-QINU`"', '"`UNIQ--vote-000011BC-QINU`"', '"`UNIQ--vote-000011BD-QINU`"' (1) ·
'"`UNIQ--vote-0000124D-QINU`"', '"`UNIQ--vote-0000124E-QINU`"', '"`UNIQ--vote-0000124F-QINU`"' (1)
10 mg (1) ·
Migraine prophylaxis: 400 mg PO daily; deficiency replacement 5-30 mg/d (1) ·
Topical: 0.5-5% cream/solution to lesions BID × 2-4 weeks; systemic IV: regimen-specific in cancer chemotherapy (1) ·
Topical: pea-sized amount to dry face at bedtime, building from 2-3×/week to nightly as tolerated; oral APL: 45 mg/m²/d in divided doses (1)
1–4 days (7–15 days for norfluoxetine) (1) ·
~0.5-2 hours (oral)'"`UNIQ--ref-00000BA3-QINU`"' (1) ·
~1-2 hours plasma (riboflavin itself); FAD/FMN tissue cofactors are continuous (1) ·
~10-20 minutes systemically (rapid hepatic and erythrocyte dihydropyrimidine dehydrogenase clearance)'"`UNIQ--ref-000011BE-QINU`"' (1)
70–90% (oral) (1) ·
Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)'"`UNIQ--ref-000011BF-QINU`"' (1) ·
Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing'"`UNIQ--ref-00000BA4-QINU`"' (1) ·
~50-60% (oral; food enhances) (1)
None (1) ·
Category C'"`UNIQ--ref-00000045-QINU`"' (1) ·
Safe at replacement and supplement doses.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Topical: avoid; systemic: contraindicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 4 results in range #1 to #4.


